Raymond James on Viking Therapeutic (VKTX): 'Our analysis of this dataset suggests semaglutide does not have a lean body mass preservation advantage'
Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $118.00 price target on Viking Therapeutic (NASDAQ: VKTX).The analyst ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)